TP53 and urinary bladder carcinoma: In our dataset, all 3 patients with MDM2 alterations had amplifications, consistent with amplification being the most frequent alteration type involving MDM2 in bladder cancer, which leads to a reduction or loss of function of p53 (36, 37).